FP 1096

Drug Profile

FP 1096

Alternative Names: Endometriosis treatment - FemmePharma; FP1096; PARDEL™ endometriosis treatment - FemmePharma

Latest Information Update: 12 Jun 2014

Price : $50

At a glance

  • Originator FemmePharma; KV Pharmaceutical Company
  • Developer FemmePharma
  • Class Hormones
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Endometriosis

Most Recent Events

  • 12 Jun 2014 Discontinued - Phase-III for Endometriosis in USA (Vaginal)
  • 29 May 2014 KV Pharmaceutical is now called Lumara Health
  • 08 Sep 2009 No development reported - Phase-III for Endometriosis in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top